title: Goserelin a GnRH-analogue as third-line therapy of refractory epithelial ovarian cancer.
abstract: Between October 1988 and March 1991, 23 ovarian cancer patients with progressive disease whilst receiving second- or third-line polychemotherapy received subcutaneously 3.6 mg Goserelin, a GnRH analogue, at monthly intervals until further tumor progression. Four patients (17.4%) achieved partial response, 7 patients (30.4%) had stable disease and 12 patients (52.2%) showed further tumor progression. Median time to tumor progression was 8.5, 5.3 and 2.1 months, respectively (Mantel test, P = 0.0003). Ten out of 11 patients who showed partial response or no change had grade 2 or grade 3 tumors. We conclude that Goserelin shows evidence of antitumor activity also in grade 2 and grade 3 ovarian carcinoma. It offers a therapeutic alternative to a group of patients, in whom we usually terminate cytotoxic treatment.
authors.affiliation: Oncologic Unit of the 1st Department of Gynecology & Obstetrics, University of Vienna and Department of Chemotherapy, University of Vienna, Austria.
authors.forename: P.
authors.initials: P
authors.lastname: Sevelda
authors.forename: N.
authors.initials: N
authors.lastname: Vavra
authors.forename: R.
authors.initials: R
authors.lastname: Fitz
authors.forename: M.
authors.initials: M
authors.lastname: Barrada
authors.forename: H.
authors.initials: H
authors.lastname: Salzer
authors.forename: M.
authors.initials: M
authors.lastname: Baur
authors.forename: C.
authors.initials: C
authors.lastname: Dittrich